GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Debt-to-EBITDA

CRISPR Therapeutics AG (LTS:0VRQ) Debt-to-EBITDA : -0.43 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CRISPR Therapeutics AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.0 Mil. CRISPR Therapeutics AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $218.9 Mil. CRISPR Therapeutics AG's annualized EBITDA for the quarter that ended in Mar. 2024 was $-543.0 Mil. CRISPR Therapeutics AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.43.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CRISPR Therapeutics AG's Debt-to-EBITDA or its related term are showing as below:

LTS:0VRQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.5   Med: -0.28   Max: 1.02
Current: -0.84

During the past 10 years, the highest Debt-to-EBITDA Ratio of CRISPR Therapeutics AG was 1.02. The lowest was -1.50. And the median was -0.28.

LTS:0VRQ's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs LTS:0VRQ: -0.84

CRISPR Therapeutics AG Debt-to-EBITDA Historical Data

The historical data trend for CRISPR Therapeutics AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Debt-to-EBITDA Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 -0.18 0.58 -0.38 -1.18

CRISPR Therapeutics AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.68 -0.47 0.80 -0.43

Competitive Comparison of CRISPR Therapeutics AG's Debt-to-EBITDA

For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-EBITDA falls into.



CRISPR Therapeutics AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CRISPR Therapeutics AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.625 + 223.007) / -202.701
=-1.18

CRISPR Therapeutics AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.992 + 218.935) / -543.016
=-0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


CRISPR Therapeutics AG  (LTS:0VRQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CRISPR Therapeutics AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines